MODERATE
61
The Alpha Score is an informational signal based on public SEC fillings. It is not investment advice.
CEOJOURNAL SIGNAL SUMMARY·GENERATED FROM PUBLIC SEC FILINGS
Owen Hughes made an open-market purchase of Xoma Royalty Corp on 2025-12-04, investing approximately $2,505,000. This is a CEOJournal signal summary placeholder — full narrative pending Claude Haiku enrichment.
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
Score Components
COMPOSITE ALPHA SCORE
61
Score calculated from open-market purchases only; 10b5-1 preplanned trades excluded; not investment advice.
OPPORTUNISM
Proxy from ownership-change magnitude. Real Opportunism signal will use %52W proximity once price data is in pipeline.
CONVICTION
Log-scaled from trade size. Real Conviction signal will use trade $ ÷ total compensation once DEF 14A data is in pipeline.
PATTERN
Placeholder — 90-day qualifying buy count requires historical Form 4 scrapes (Phase 2).
CLUSTER
Count of other insiders buying the same ticker in our current dataset window.
TRACK RECORD
Placeholder — executive tenure × prior buy P&L requires historical price tracking (Phase 2).
FORM 4 TRANSACTION HISTORYSOURCE: SEC EDGAR
| DATE | TRANSACTION TYPE | CODE | SHARES | PRICE | TOTAL VALUE | 10b5-1 | SCORE |
|---|---|---|---|---|---|---|---|
| Dec 04, 2025 | Open-Market Purchase | P | 100,000 | $25.05 | $2,505,000 | N/A | 61 |
Data sourced from SEC EDGAR Form 4 filings, updated within 24 hours.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
EXECUTIVE PROFILE
Owen Hughes
CEO
Owen Hughes has served as Chief Executive Officer of Xoma Royalty Corp since January 2024, after previously holding the positions of Executive Chairman of the Board and Interim Chief Executive Officer since January 2023. He was the Chief Executive Officer of Sail Bio, Inc. since February 2022 and co-founder and CEO of Cullinan Therapeutics, Inc. from September 2017 to October 2021. Prior to these roles, he served as Chief Business Officer and Head of Corporate Development at Intarcia Therapeutics, Inc. and spent 16 years on Wall Street in various capacities.
EDUCATION
- Dartmouth College (B.A. in History)
BOARD SEATS
- Ikena Oncology, Inc. · Chairman of the Board
- C4 Therapeutics · Board Member
- Radius Health, Inc. · Board Member
- Translate Bio, Inc. · Board Member
- FS Development Corp. II · Board Member
COMPENSATION & OWNERSHIP ·SOURCE: DEF 14A PROXY
ANNUAL BASE SALARY
$707,940
TOTAL COMPENSATION
$1,140,207
SHARES HELD
200,563
EST. HOLDINGS VALUE
$8.37M
as of May 30, 2026 close
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
RELATED SIGNALS